

**SESSION 7: VACCINES & ADJUVANTS TO ELICIT IMMUNITY IN THE MUCOSA**

Moderator: Ali Harandi  
(University of Gothenburg, Gothenburg, Sweden)

09.00-09.30

**'Vaccines and adjuvants for immunity to genital herpes: Opportunities and challenges'**

Ali Harandi  
(University of Gothenburg, Gothenburg, Sweden)

09.30-10.00

**'Differential mucosal and systemic immune responses to parenteral or sublingual delivery of VLP-alum formulated viral antigens in humans'**

David J.M. Lewis  
(St. George's University of London, London, UK)

10.00-10.15 Coffee Break

**SESSION 8: LATE BREAKING PRESENTATIONS**

Moderator: Jeff Ulmer  
(Novartis Vaccines, Cambridge, Massachusetts, USA)

10.15-10.35

**'Vaccine platforms to control Lassa Fever'**

Igor S. Lukashevich, Peter J. Bredenbeek and Peter Pushko  
(University of Maryland School of Medicine, Baltimore, Maryland, USA)

10.35-10.55

**'Immunization of sheep with a combination of intimin, EspA and EspB decreases Escherchia coli O157:H7 shedding'**

M. Atef Yekta, B.M Goddeeris, D. Vanrompay and E. Cox  
(University of Ghent, Ghent, Belgium)

10.55-11.15

**'Antibiotic free DNA vaccine vectors with improved transgene expression and innate immune activation'**

Jeremy Luke, Justin Vincent, Clague Hodgson and James Williams  
(Nature Technology Corporation, Lincoln, Nebraska, USA)

Conference Programme – Posters (On display throughout the conference)

Poster 101

**'Adjuvants that stimulate TLR3 or NLRP3 pathways enhance the efficiency of influenza virus-like particle vaccines in aged mice'**

Dilhari R. DeAlmeida et al. (University of Pittsburgh, USA)

Poster 102

**'Combination vaccine of norovirus virus-like particles (VLPs) and rotavirus VP6 protein for childhood gastroenteritis'**

Suvi Lappalainen et al. (University of Tampere, Finland)

11.15-11.35

**'Expression of mycobacterial antigens by vesicular stomatitis virus replicons'**

Miriam Bolz, Anita M. Dreyer, Jean-Pierre Dangy, Gert Zimmer and Gerd Pluschke  
(Swiss Tropical and Public Health Institute, Basel, Switzerland)

**SESSION 9: Public policies for development of vaccines and adjuvants against emerging infectious diseases**

Moderator: Ole Olsen  
(European Commission, Brussels, Belgium)

11.40-12.10

**'Making vaccines for neglected and emerging diseases: Role of the public sector'**

Ole Olsen (European Commission, Brussels, Belgium)

12.10-12.40

**'Whooping cough: a public health and producer's perspective'**

Marcel Thalen  
(Synco Bio Partners BV, Amsterdam, The Netherlands)

**SESSION 10: PANEL DISCUSSION**

12.40-13.30

**'Challenges for developing, testing, producing and licensing vaccines and adjuvants for emerging infectious diseases'**

Moderator: Ted Ross  
(University of Pittsburgh, Pittsburgh, Pennsylvania, USA)

Panel Discussion Members to be confirmed

13.30

**Closing Remarks By**

Ted Ross  
(University of Pittsburgh, Pittsburgh, Pennsylvania, USA)

Lunch

Poster 103

**'Virus-like particles (VLPs) and P-particles as vaccine candidates for norovirus gastroenteritis: A comparison of the immune responses in mice'**

Kirsi Nurminen et al. (University of Tampere, Finland)

This programme is correct at time of printing. However the organizers reserve the right to make any alterations that may be required in the interests of the integrity of the conference programme.



Vaccines & Adjuvants for Emerging Infectious Diseases

FINAL ORAL & POSTER PROGRAMMES

ANNOUNCING A NEW INTERNATIONAL CONFERENCE

VACCINES & ADJUVANTS FOR EMERGING INFECTIOUS DISEASES

PREVENTION OF EMERGING VIRAL, BACTERIAL AND OTHER INFECTIONS

VAEID 2011, 11-13 MAY 2011, HALF MOON RESORT, MONTEGO BAY, JAMAICA

Advisory Scientific Panel

- Ted M. Ross (University of Pittsburgh, USA) · Ali Harandi (University of Gothenburg, Sweden)  
Farrokh Modabber (DNDI, Geneva, Switzerland) · Eszter Nagy (Intercell AG, Vienna, Austria)  
Ole F. Olesen (European Commission, Brussels, Belgium) · David Lewis (St. George's University of London, UK)  
James P. Nataro (University of Maryland, USA) · Stephen Hoffman (Sanaria Inc., Rockville, Maryland, USA)  
Steve Reed (IDRI, Seattle, Washington, USA) · Michael Farzan (Harvard Medical School, USA)  
Chris Basler (Mount Sinai School of Medicine, USA) · Penny Hitchcock (The Tauri Group, Alexandria, Virginia, USA)  
Felicity J. Burt (University of the Free State, Bloemfontein, South Africa)  
Mark Heise (University of North Carolina, USA) · Susan Szathmary (GalenoBio Inc., USA)  
Ian Ramshaw (Australian National University, Canberra, ACT, Australia)  
Mike Diamond (Washington University, St. Louis, Missouri, USA)  
Jennifer R. Hanneschlager (Tiber Creek Partners, Washington DC, USA)  
Doug S. Reed (University of Pittsburgh, USA) · Tom Monath (Kleiner Perkins Caufield & Byers, USA)  
Rob Lambkin-Williams (Retroscreen Virology Ltd, London, UK) · Les Baillie (University of Cardiff, Wales, UK)  
Alessandro Sette (La Jolla Institute for Allergy & Immunology, USA) · Jeffrey Ulmer (Novartis Vaccines, USA)  
Niranjan Sardesai (INOVIO Pharmaceuticals, Blue Bell, Pennsylvania, USA)

Sponsors

The VAEID 2011 Advisory Scientific Panel and the organizers would like to acknowledge the support of the following sponsors:



08.15 Onwards Conference Registration

09.00

Welcome & Opening Remarks

Ted M. Ross

(University of Pittsburgh, Pittsburgh, Pennsylvania, USA)

### SESSION 1: OPENING PLENARY SESSION

Moderator: Ted M. Ross

(University of Pittsburgh, Pittsburgh, Pennsylvania, USA)

09.00-09.45

**'Immunome-derived vaccines – The next wave of vaccine design'**

Annie DeGroot, Lenny Moise and Bill Martin  
(University of Rhode Island/Epivax Inc., Providence, Rhode Island, USA)

09.45-10.30

**'Immunomic analysis of complex pathogens'**

Alex Sette (LIAI, La Jolla, California, USA)

10.30 – 11.00

Coffee Break

### SESSION 2: PLENARY SESSION

Moderator: Alex Sette (LIAI, La Jolla, California, USA)

11.00-11.45

**'Vaccine development for EV71 – a new emerging viral infection in the Far East'**

Shan Lu

(University of Massachusetts, Massachusetts, USA)

11.45-12.30

**'Defining the epitope specificity of the antibody response generated by memory B and long lived plasma cells after vaccination or infection with West Nile Virus'**

Mike Diamond

(Washington University, St. Louis, Missouri, USA)

12.30-16.00

Lunch & Leisure Time

### SESSION 3: VACCINES & ADJUVANTS AGAINST ARBOVIRUSES

Moderator: Mike Diamond

(Washington University, St. Louis, Missouri, USA)

16.00-16.30

**'DNA vaccination to generate Chikungunya virus-specific immunity'**

Karuppiah Muthumani, Niranjana Y. Sardesai, J. Joseph Kim and David B. Weiner

(University of Pennsylvania, Philadelphia, Pennsylvania, USA)

16.30-16.50

**'Protection against aerosolized Rift Valley Fever virus infection using DNA plasmid and replicon-based vaccines'**

Nitin Bhardwaj and Ted M. Ross

(University of Pittsburgh, Pittsburgh, Pennsylvania, USA)

16.50-17.10

**'Immunogenicity of a novel CCHF vaccine, expressed in a poxviral vaccine vector'**

Edmund Newman, Karen Buttigieg, Roger Hewson and Miles W. Carroll

(Health Protection Agency, Porton Down UK)

17.10-17.30

**'Subunit vaccine formulations based on recombinant envelope proteins of Chikungunya virus elicit balanced Th1/Th2 response and neutralizing antibodies in mice'**

M.M. Parida, M. Khan, R. Dhanwani and P.V.L. Rao  
(DRDE, Gwalior, MP, India)

18.00-19.00

VAEID 2011 Welcome Drinks Reception

### SESSION 4: VACCINES & ADJUVANTS AGAINST RESPIRATORY INFECTIONS

Moderator: Shan Lu

(University of Massachusetts, Massachusetts, USA)

09.00-09.30

**'Integrating viral pathogenesis, immunology, and systems biology to develop safer vaccines against emerging respiratory viruses'**

Ralph Baric (University of North Carolina, USA)

09.30-09.50

**'Computationally optimized broadly reactive antigen (COBRA): A novel strategy for developing a broadly reactive vaccine against H5N1 influenza'**

Brendan M. Giles, Stephanie J. Bissel, Clayton A. Wiley and Ted M. Ross

(University of Pittsburgh, Pittsburgh, Pennsylvania, USA)

09.50-10.10

**'Vaccination against influenza H5N1 CDC-RG using antiviral cinnamon fraction'**

Immanuel Kalily, Emily Bernstein and Michael Ovadia  
(Tel Aviv University, Tel Aviv, Israel)

10.10-10.30

**'Pre-existing antibodies to seasonal influenza A viruses elicit cross-reactive immune responses against emerging pandemic H1N1 influenza viruses'**

Donald M. Carter, Joshua L. Cherry, David J. Lipman and Ted M. Ross

(University of Pittsburgh, Pittsburgh, Pennsylvania, USA)

10.30-11.00

Coffee Break

### SESSION 5: PROTOZOANS & PARASITES

Moderator: Stephen Hoffman

(Sanaria Inc, Rockville, Maryland, USA)

11.00-11.45

**'Adjuvanting a whole-organism live sporozoite vaccine against malaria'**

Stephen Hoffman

(Sanaria Inc, Rockville, Maryland, USA)

11.45-12.05

**'Antibodies specific for the cysteine-rich protective antigen of Plasmodium falciparum inhibit parasite growth in vitro and in vivo'**

Anita M. Dreyer, Hugues Matile,

Petro Papaastogiannidis, Jolanda Kamber, Sergio Wittlin and Gerd Pluschke

(Swiss Tropical and Public Health Institute, Basel, Switzerland)

12.05-12.25

**'MOMP-based DNA vaccination against Chlamydia trachomatis infection in a pig model'**

K. Schautteet, E. Stuyven, E. Cox and D. Vanrompuy  
(University of Ghent, Ghent, Belgium)

12.25-16.00

Lunch & Leisure Time

### SESSION 6: NOVEL ADJUVANTS & IMPORTANCE OF ROUTE & DELIVERY OF VACCINES & ADJUVANTS

Moderator: Kate E. Broderick

(INOVIO Pharmaceuticals, USA)

16.00-16.30

**'Adjuvants and delivery systems as potential enabling technologies for emerging infectious diseases'**

Jeff Ulmer

(Novartis Vaccines, Cambridge, Massachusetts, USA)

16.30-17.00

**'A multiagent DNA vaccine for Venezuelan eastern and western equine encephalitis viruses delivered by electroporation'**

Lesley Dupuy (USAMRIID, Fort Detrick, Maryland, USA)

17.00-17.20

**'Costimulation as a novel platform for the development of vaccines'**

Haval Shirwan

(University of Louisville, Louisville, Kentucky, USA)

17.20-17.40

**'Combining DNA vaccines of military interest with novel dermal delivery methods results in protective immunity'**

Kate E. Broderick

(INOVIO Pharmaceuticals, Blue Bell, Pennsylvania, USA)

17.40-18.00

**'IC31<sup>®</sup>, a potent parenteral and mucosal vaccine adjuvant that stimulates the induction of humoral and type 1 T cell responses'**

Benjamin Wizel (InterCell AG, Vienna, Austria)

18.00-18.20

**'Chitosan for prophylactic and therapeutic antigen delivery'**

Sevda Senel (Hacettepe University, Ankara, Turkey)

18.20-18.40

**'An adjuvant for a live recombinant adenovirus vaccine'**

Moriya Tsuji

(Aaron Diamond AIDS Research Center, New York, USA)

Free Evening for Delegates